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Abstract
Central to the pathogenesis of Alzheimer's disease (AD) is the conversion of normal, soluble β-
amyloid (sAβ) to oligomeric, fibrillar Aβ. This process of conformational conversion can be
influenced by interactions with other proteins that can stabilize the disease-associated state; these
proteins have been termed 'pathological chaperones'. In a number of AD models, intervention that
block soluble Aβ aggregation, including β-sheet breakers, and compounds that block interactions
with pathological chaperones, have been shown to be highly effective. When combined with early
pathology detection, these therapeutic strategies hold great promise as effective and relatively
toxicity free methods of preventing AD related pathology.
Introduction
Formation of β-amyloid (Aβ) fibrils and deposition of Aβ
in the brain parenchyma, or in the brain's vessels, occurs
in the setting of increased Aβ peptide concentrations
[1,2]. Initially, conditions do not favor aggregation of
fibrils, but once a critical nucleus has been formed, condi-
tions change to favor aggregation in an exponential man-
ner. Any available monomer becomes instantly entrapped
in an aggregate or fibril. Several compounds – for exam-
ple, Congo red [3], anthracycline [4], rifampicin [5], ani-
onic sulphonates [6], and melatonin [7] – can interact
with Aβ and prevent its aggregation into oligomers and
fibrils in vitro, reducing toxicity. These oligomeric struc-
tures have been associated with the greatest toxicity [8].
Several Aβ homologous peptides have been identified that
have amino acid substitutions using residues such as pro-
line and can bind to Aβ oligomers and fibril structures,
leading to disruption of the β-sheet conformation [9-12].
These peptides have been termed β-sheet breakers. An
advantage of such compounds, in comparison to other
putative therapeutic approaches for AD, such as vaccina-
tion, is that they specifically target the abnormal confor-
mation of Aβ and will not disrupt any possible normal
function of the soluble Aβ peptide. Several modifications
have been used to extend the serum half-life and increase
the blood-brain barrier (BBB) permeability of these β-
sheet breakers. Permanne et al. [13], using a BBB permea-
ble pentapeptide (iAβ5), were able to demonstrate a
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reduction of Aβ load in AD Tg mice compared to an age-
matched control group. Of interest, a similar concept of β-
sheet breakers appears to be applicable to other protein
conformational disorders caused by prions [14].
Pathological chaperone inhibitors
Aβ homologous peptides can spontaneously aggregate
and form fibrils in vitro; however, in vivo this process
appears more dependant on Aβ pathological chaperones.
This group of proteins actively promotes conformational
transformation by increasing the β-sheet content of these
disease-specific proteins, stabilizing their abnormal struc-
ture [15-17]. Examples in Alzheimer's disease (AD)
include apolipoprotein E (apoE), especially its E4 isoform
[16,18], α1-antichymotrypsin [19], and C1q complement
factor [20,21]. In their presence, the formation of Aβ
fibrils in a solution of soluble Aβ monomers becomes
much more efficient [16,19]. These 'pathological chaper-
one' proteins have been found histologically and bio-
chemically in association with fibrillar Aβ deposits
[15,22-24], but not in preamyloid aggregates, which are
not associated with neuronal toxicity [25-27]. Inheritance
of the apoE4 isoform has been identified as the major
genetic risk factor for sporadic, late-onset AD [28] and cor-
relates with an earlier age of onset and greater Aβ deposi-
tion in an allele-dose-dependent manner [28,29]. On the
other hand, epidemiological data suggest that inheritance
of the E2 allele has a protective effect. In vitro all apoE iso-
forms can propagate the β-sheet content of Aβ peptides
promoting fibril formation [16,23], with apoE4 being the
most efficient [16]. The critical dependence of Aβ deposi-
tion in plaques on the presence of apoE has also been con-
firmed in AD Tg amyloid precursor protein (APP)V717F/
apoE-/- mice, which have a delayed onset of Aβ deposition,
a reduced Aβ load, and no fibrillar Aβ deposits compared
with APPV717F/apoE+/+  Tg mice. APPV717F/apoE+/-  mice
demonstrate an intermediate level of pathology [30-33].
Neutralization of the chaperoning effect of apoE would
therefore potentially have a mitigating effect on Aβ accu-
mulation. ApoE binds hydrophobically to amino acids
12–28 of Aβ, forming SDS-insoluble complexes [34-36].
Ma et al. [37] have demonstrated that a synthetic peptide
homologous to this sequence of Aβ can be used as a com-
petitive inhibitor of the binding of full length Aβ to apoE,
resulting in reduced fibril formation in vitro and increased
survival of cultured neurons. Several modifications to
Aβ12–28, including the replacement of a valine for pro-
line at position 18 (Aβ12–28P), made this peptide non-
toxic, non-fibrillogenic, and prevented any potential for
co-deposition on existing Aβ plaques. Further modifica-
tions included protection of its amino and carboxyl ter-
mini, and using D-amino acids resulted in an extended
serum half-life (62 ± 18 minutes, mean ± standard devia-
tion. These modifications did not limit its ability to block
the apoE-Aβ interaction (Ki  = 11.37 nM) [38,39].
Although Aβ12–28P had a limited serum half-life, it was
able to cross the BBB, exerting a therapeutically prolonged
effect. Treatment of APPK670N/M671L/PS1M146L, and
APPK670N/M671L AD Tg mice with Aβ12–28P resulted in a
significant reduction of Aβ deposition in brain paren-
chyma and in brain vessels [39]. Furthermore, treatment
with Aβ12–28P prevented memory decline in single APP
Tg mice. Measurement of Aβ levels in the brain homoge-
nate revealed a significant reduction in the absolute Aβ
level while the concentrations of the soluble Aβ fraction
and Aβ oligomers remained stable during treatment [39].
This observation is important in light of a concern regard-
ing the blocking of the apoE-Aβ interaction and that this
form of therapeutic interference could destabilize fibrillar
Aβ assemblies, and impair apoE-mediated Aβ clearance,
potentially increasing brain levels of soluble Aβ, thus
favoring the formation of toxic oligomers [8,40]. During
treatment with Aβ12–28P, no signs of toxicity, including
systemic amyloidosis or disturbance of vascular integrity
leading to cerebral hemorrhages (as observed with some
vaccination approaches [39]), were noted. The treatment
outcome with Aβ12–28P could not be attributed to an
immunization effect since there were no significant
changes in the serum titer of anti-Aβ antibodies before
and after the treatment of AD Tg animals. Thus, interfer-
ence with the apoE-Aβ interaction in vivo appears to have
a net effect of increasing Aβ clearance and reducing the
absolute Aβ level in the brain, producing a cognitive ben-
efit. Further development of ligands inhibiting the apoE-
Aβ interaction, potentially making them suitable for clin-
ical application, should be aggressively pursued.
Of interest, Pepys and co-workers [41] have developed a
ligand that chelates serum amyloid-P component. Serum
amyloid-P component, along with apoE, binds to amy-
loid fibrils in vivo in amyloid-A primary systemic amy-
loidosis, and inhibits the normal degradative process of
amyloid-A [42]. Both disease model animals and affected
humans treated with this compound in phase I/II clinical
trials demonstrated reduced amyloid-A deposition [41].
A similar treatment concept is being developed based on
inhibiting the interaction between glycosaminoglycans
and Aβ fibrils [6]. Neurochem Inc. is conducting clinical
trials to determine the efficacy of 3-amino-1-propanesul-
fonic acid (3APS), a synthetic sulphated glycosaminogly-
can mimetic designed to compete with naturally occurring
glycosaminoglycans in their binding to Aβ to prevent its
deposition http://www.neurochem.com/ResearchActivi
ties.htm. The efficacy of this compound is being tested for
AD and cerebral amyloid angiopathy under two different
brand names, Alzhemed™ and Cerebril™, respectively. The
phase II clinical trial of Alzhemed™ (tramiprosate) dem-
onstrated a good safety profile, with the most frequently
reported adverse events being nausea and vomiting, theBMC Neuroscience 2008, 9(Suppl 2):S5 http://www.biomedcentral.com/1471-2202/9/S2/S5
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occurrence of which appeared to be dose related. This
multi-centre, double-blind, placebo-controlled study
recruited 58 patients who received either tramiprosate
(100 mg, 200 mg or 300 mg daily) or placebo. Results of
this trial indicated that tramiprosate reduced the Aβ1–42
concentration in the cerebrospinal fluid and stabilized
cognitive decline (monitored using the Mini-Mental State
Examination (MMSE) and Alzheimer's Disease Assess-
ment Scale-cognitive subscale (ADAS-cog) scales) com-
pared with the control group [43]. Unfortunately, the
North American phase III clinical trial of tramiprosate,
which finished in late 2007, did not provide clear enough
benefit in a large population. The clinical data gathered by
this trial are being subjected to secondary statistical anal-
ysis. Currently, the prospect of FDA approval for tramip-
rosate remains unclear.
Another class of compounds characterized by inherent
anti-Aβ aggregation properties in vivo comprises the
cyclohexanehexol (inositol) stereoisomers. These com-
pounds are naturally occurring sugars characterized by
good gastrointestinal absorption, making them attractive
candidates for clinical development. When administered
orally to AD Tg mice, the cyclohexanehexol stereoisomers
scyllo-cyclohexenehexol and epi- cyclohexenehexol
reduced several disease features, including impaired cog-
nition, altered synaptic physiology, and cerebral Aβ depo-
sition [44]. Clinical trials of scyllo-cyclohexanehexol are
currently entering a multi-center phase II trial under the
name ELND005.
The US phase II clinical trial of NC-758 (Cerebril™) for the
prevention of hemorrhagic stroke due to cerebral amyloid
angiopathy has recently finished. This multi-center, rand-
omized, double-blind and parallel-designed study was
conducted at five centers, enrolled 24 cerebral amyloid
angiopathy (CAA) patients, and found no safety concerns
related to the use of NC-758. Neurochem Inc. has also
recently successfully finished a phase II/III clinical trial of
1,3-propanedisulfonate (Fibrillex™), a compound
designed to treat amyloidosis A, which is associated with
a number of systemic, chronic inflammatory diseases,
including rheumatoid arthritis and Crohn's disease. Its
mechanism of action is analogous to that of tramiprosate.
Based on the results of this trial the company has filed for
market approval.
Necessity for early diagnosis and treatment
For maximal benefit, it is likely that all of the interven-
tions discussed above will need to be initiated at the ear-
liest stages of AD pathology [45]. From AD models,
therapeutic strategies to prevent and remove amyloid dep-
osition using methods such as vaccination are very effec-
tive at preventing cognitive deficits when initiated at the
time deposition first starts. However, when the same treat-
ment is administered after deposits are well-established
there are no cognitive benefits [46]. In AD patients it is
estimated that mild cognitive impairment slowly devel-
ops over 10–30 years prior to the presentation of pathol-
ogy [47,48]. In the active vaccination study, which
targeted early clinical stage AD, patients showed a very
modest cognitive benefit [49,50] despite the fact that
autopsies on four study participants indicated that the
vaccine had produced a significant reduction in amyloid
plaques [51]. Positron emission tomography (PET) imag-
ing of amyloid binding ligands can detect amyloid depo-
sition at early stages [52] and similar methods are being
developed for amyloid detection by magnetic resonance
imaging (MRI) [53]. These methods will be critical in
identifying patients who are at risk of developing clinical
AD and who might benefit from preventing Aβ aggrega-
tion and deposition therapies.
Conclusion
Numerous therapeutic interventions are currently being
developed for AD. It is likely that, in the future, multi-
modal therapies will be tailored to individual patients
based on their genotype, immune status, and pathological
stage of their disease. However, β-sheet breakers and path-
ological chaperone inhibitors are likely to be among the
most effective and safest strategies.
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